Metastatik Endometrioid Endometrial Karsinom Hastalarında Tedavi Seçeneklerinin Sağkalım Üzerine Etkisi

Abstract

Endometrium kanseri (EK) gelişmiş ülkelerde en sık görülen jinekolojik kanserdir. Obezite en önemli risk faktörü olarak kabul edilmektedir. Endometrium kanserleri içerisinde en sık görülen alt tip endometrioid endometrial karsinomdur (EEK). Çalışmamızda metastatik EEK hastalarının demografik ve klinikopatolojik özelliklerini, kullanılan tedavi yöntemlerinin sağ kalıma etkisini incelemeyi amaçladık. Hastaların medyan yaşı 58 (39,4-81,9) idi. On altı hastanın hastaneye başvuru şikayeti vajinal kanamaydı. Medyan takip süresi 43 (0,2-104,3) aydı. Hastaların medyan progresyonsuz sağkalım (PS) süresi 39,9 ay (%95 güven aralığı (GA): 35,0-79,1), medyan genel sağkalım (GS) süresi 59,1 ay (%95 GA: 39,1-80,8) saptandı. Kemoradyoterapi alan hastaların PS ve GS süresi sadece kemoterapi ile tedavi edilen hastalara göre istatistiksel anlamlı olarak daha uzundu (log-rank testi, PS için p=0,012, GS için p=0,015). Çalışmamız metastatik evrede seçilmiş hasta grubunda kemoradyoterapinin tercih edilebileceğini desteklemektedir.

Keywords

• Endometrial endometrioid karsinom
• metastaz
• kemoterapi
• kemoradyoterapi
• sağkalım.

The Effect of Treatment Options on Survival in Patients with Metastatic Endometrioid Endometrial Carcinoma

Abstract

Endometrial cancer (EC) is the most common gynecological malignancy in developed countries. Obesity is known as the major risk factor for endometrial cancer. The most common subtype of endometrial cancer is endometrioid endometrial carcinoma (EEC). Our study aims to investigate the demographic and clinicopathological characteristics of metastatic EEC patients and the effect of treatments on survival. The median age of the patients was 58 (39.4-81.9) years. Sixteen patients presented with abnormal vaginal bleeding. The median follow-up time was 43 (0.2-104.3) months. The median progression-free survival (PFS) was 39.9 months (95% confidence interval (CI): 35.0-79.1), and the median overall survival (OS) was 59.1 months (95% CI: 39.1-80.8). Patients receiving chemoradiotherapy had significantly longer PFS and OS than patients treated with chemotherapy alone (log-rank test, p=0.012 for PFS, p=0.015 for OS). Our study supports that chemoradiotherapy might be a treatment option for selected patient groups in the metastatic stage.

Keywords

• Endometrioid endometrial carcinoma
• metastasis chemotherapy
• chemoradiotherapy
• survival.

References

1. 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209-49.
2. 2. Lee NK, Cheung MK, Shin JY, Husain A, Teng NN, Berek JS, et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstetrics & Gynecology. 2007;109(3):655-62.
3. 3. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Giugliano D. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2014;45(1):28-36.
4. 4. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human reproduction update. 2014;20(5):748-58.
5. 5. Ali AT. Reproductive factors and the risk of endometrial cancer. International Journal of Gynecologic Cancer. 2014;24(3).
6. 6. Zhang Y, Liu H, Yang S, Zhang J, Qian L, Chen X. Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis. The International journal of biological markers. 2014;29(1):e21-e9.
7. 7. Obstetricians ACo, Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstetrics and gynecology. 2005;106(2):413-25.
8. 8. Kurman RJ, Maria LC, Herrington CS. World Health Organisation classification of tumours of the female reproductive organs. International Agency for Research on Cancer, 2014.

9. 9. Ueda SM, Kapp DS, Cheung MK, Shin JY, Osann K, Husain A, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. American journal of obstetrics and gynecology. 2008;198(2):218. e1-. e6.
10. 10. Dunton CJ, Balsara G, McFarland M, Hernandez E. Uterine papillary serous carcinoma: a review. Obstetrical & gynecological survey. 1991;46(2):97-102.
11. 11. Obstetricians ACo, Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstetrics and gynecology. 2005;106(2):413-25.
12. 12. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology. 2013;24:vi33-vi8.
13. 13. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of clinical oncology. 2006;24(1):36-44.
14. 14. Mundt AJ, McBride R, Rotmensch J, Waggoner SE, Yamada SD, Connell PP. Significant pelvic recurrence in high-risk pathologic stage I–IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. International Journal of Radiation Oncology* Biology* Physics. 2001;50(5):1145-53.
15. 15. Aoki Y, Kase H, Watanabe M, Sato T, Kurata H, Tanaka K. Stage III endometrial cancer: analysis of prognostic factors and failure patterns after adjuvant chemotherapy. Gynecologic oncology. 2001;83(1):1-5.
16. 16. National Comprehensive Cancer Network. Uterine Neoplasms, Version 3.2021. https://www.nccn.org/professionals /physician_gls/pdf/uterine.pdf
17. 17. Miller D, Filiaci V, Fleming G, Mannel R, Cohn D, Matsumoto T, et al. Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecologic oncology. 2012;125(3):771.
18. 18. Dimopoulos MA, Papadimitriou CA, Georgoulias V, Moulopoulos LA, Aravantinos G, Gika D, et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecologic oncology. 2000;78(1):52-7.
19. 19. Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. British journal of cancer. 2007;96(11):1639-43.
20. 20. Vale CL, Tierney J, Bull SJ, Symonds PR. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database of Systematic Reviews. 2012(8).
21. 21. Lester-Coll NH, Park HS, Rutter CE, Corso CD, Young MR, Ratner ES, et al. Who benefits from chemoradiation in stage III–IVA endometrial cancer? An analysis of the National Cancer Data Base. Gynecologic oncology. 2016;142(1):54-61.
22. 22. Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. New England Journal of Medicine. 2019;380(24):2317-26.
23. 23. Aalders J, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecologic oncology. 1984;17(1):85-103.
24. 24. Cormio G, Lissoni A, Losa G, Zanetta G, Pellegrino A, Mangioni C. Brain metastases from endometrial carcinoma. Gynecologic oncology. 1996;61(1):40-3.
25. 25. Shiohara S, Ohara M, Itoh K, Shiozawa T, Konishi I. Successful treatment with stereotactic radiosurgery for brain metastases of endometrial carcinoma: a case report and review of the literature. International Journal of Gynecologic Cancer. 2003;13(1).